Elsevier Sponsors Royal Australian Chemical Institute's 2010/11 Organic Division Lectureship Award
The Lectureship provides the opportunity for newly appointed staff to achieve broader recognition and exposure at an early stage of their career
Neuchâtel, Switzerland, March 29, 2010 -- Elsevier Properties SA today announced that Reaxys® is to sponsor the Royal Australian Chemical Institute’s (RACI) 2010/11 Organic Division Lectureship for Recently Appointed Staff award.
The award is open to all RACI members who have been appointed to their first academic or industrial position within the past five years. The award winner will be given the opportunity to present a lecture in at least six Australian state capitals and/or major regional centres during the year of the lectureship.
The Organic Division of RACI established the annual lectureship to provide funding for outstanding early career organic chemists to travel around Australia and present the results of their research work.
Reaxys® is a web-based search and retrieval system for chemical compounds, bibliographic data and chemical reactions. It is owned and protected by Elsevier Properties SA and used under license.
David Evans PhD, Scientific Affairs Director at Elsevier Properties SA said today: “We are proud to provide sponsorship for this award. The Organic Division Lectureship provides a unique opportunity for chemists in the early stages of their careers. We want to celebrate their achievements and give them the recognition they deserve.”
Nominations for the 2010/11 Organic Division Lectureship award should be submitted to the Chair of the RACI Organic Division (email@example.com). Nominations close April 30, 2010. Details of the award can be found on the RACI web site at: http://www.raci.org.au/national/awards/organiclectureship.html
# # #
About Elsevier Properties SA
Elsevier Properties SA is a center of excellence within Reed Elsevier for the management of intellectual property. Elsevier Properties SA owns the PharmaPendium, Beilstein and Reaxys databases. Trademarks including Reaxys®, PharmaPendium™ and The Lancet® are owned and protected by Elsevier Properties SA and used under license. For additional information see www.reedelsevier.com.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).